Advertisement
Advertisement
U.S. Markets open in 4 hrs 53 mins
Advertisement
Advertisement
Advertisement
Advertisement

Scholar Rock Holding Corporation (2QK.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
7.30+0.10 (+1.39%)
As of 08:20AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.20
Open7.30
Bid7.35 x N/A
Ask7.60 x N/A
Day's Range7.30 - 7.30
52 Week Range4.02 - 30.40
Volume495
Avg. Volume67
Market Cap259.068M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-2.33
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.25
  • Business Wire

    Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., September 22, 2022--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022. The award is subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Plan (the "Plan") and form of st

  • Business Wire

    Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

    CAMBRIDGE, Mass., September 20, 2022--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

  • Benzinga

    Analyst Builds Bullish Case For This Neuromuscular Company, Sees 200% Upside

    HC Wainwright has assumed coverage on Scholar Rock Holding Corp (NASDAQ: SRRK) with a Buy rating and price target of $30. The analyst writes that with a positive readout from the Phase 2 TOPAZ study under their belt, Scholar Rock’s apitegromab (SRK-015) is shaping to be a transformative therapeutic for Type 2/3 Spinal Muscular Atrophy (SMA). HC Wainwright says that recent 24-Month TOPAZ extension data further convinces that apitegromab can solidify a place in the SMA market (2025 est. approval)

Advertisement
Advertisement